CARBATROL (carbamazepine) by Takeda is cytochrome p450 3a4 inducers [moa]. Approved for mood stabilizer [epc]. First approved in 1997.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
CARBATROL is an extended-release oral capsule formulation of carbamazepine, a cytochrome P450 3A4 inducer approved in 1997 for mood stabilization. It is indicated as a mood stabilizer and works by modulating sodium channels and enhancing GABAergic neurotransmission. The extended-release formulation allows for reduced dosing frequency compared to immediate-release alternatives.
Product is in late-stage lifecycle with modest Part D spending of $4M and declining relevance, suggesting smaller commercial team and focus on retention rather than growth initiatives.
Cytochrome P450 3A4 Inducers
Mood Stabilizer
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole
A Trial to Examine the Interaction of Repinatrabit With Ethinyl Estradiol/Norethindrone, Metformin,Carbamazepine, Rosuvastatin, and Methotrexate When Administered Together
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
To Assess the Enzyme Inducing Effects of Carbamazepine on the PK of Mirdametinib in Healthy Participants
A Study to Learn if Multiple Doses of the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine PF-07248144
Worked on CARBATROL at Takeda? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCARBATROL offers limited career opportunity with zero linked job postings and declining commercial momentum as LOE approaches. Positions on this product typically focus on defending market share against generics and managing the transition to post-exclusivity strategies rather than driving growth.